In EGFR-mutant non-small cell lung cancer (NSCLC), CD70 has been discovered as being highly expressed on drug-resistant cancer cells.
The preclinical research was led by Monique Nilsson, Ph.D., and corresponding author John Heymach, M.D., Ph.D., chair of Thoracic/Head and Neck Medical Oncology. The researchers discovered that CD70, a cell surface protein normally found on immune cells, is highly overexpressed in resistant cells as well as in the residual cancer cells immediately following TKI treatment....
↧